Asset / Drug

Haleon

Drug and asset intelligence for Haleon with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Recent signals(2)

RegulatoryJuly 3, 2026

The FDA has accepted a supplemental application for ABREVA, a cold sore treatment containing docosanol.

RegulatoryJuly 1, 2026

The FDA has approved the supplemental application for Children's Advil-Flavored, containing ibuprofen.

No catalysts indexed for this entity yet.

Topline Data

Monitor the timeline for the FDA's decision on the supplemental application and any subsequent marketing strategies from Haleon.

July 3, 2026 · N/A

Topline Data

Monitor sales performance and any competitor reactions in the pediatric OTC pain management market.

July 1, 2026 · N/A

No related entities indexed yet.

Newsletter

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.